Nippon Life Global Investors Americas Inc. Trims Stock Holdings in Zoetis Inc (NYSE:ZTS)

Nippon Life Global Investors Americas Inc. trimmed its holdings in Zoetis Inc (NYSE:ZTS) by 39.6% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 26,820 shares of the company’s stock after selling 17,580 shares during the quarter. Nippon Life Global Investors Americas Inc.’s holdings in Zoetis were worth $3,342,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of ZTS. Vanguard Group Inc. grew its stake in Zoetis by 1.0% in the second quarter. Vanguard Group Inc. now owns 36,765,577 shares of the company’s stock worth $4,172,526,000 after purchasing an additional 346,167 shares in the last quarter. Polen Capital Management LLC grew its stake in Zoetis by 0.9% in the second quarter. Polen Capital Management LLC now owns 10,188,554 shares of the company’s stock worth $1,156,299,000 after purchasing an additional 86,364 shares in the last quarter. Nuveen Asset Management LLC grew its stake in Zoetis by 40,874.9% in the second quarter. Nuveen Asset Management LLC now owns 7,078,826 shares of the company’s stock worth $803,376,000 after purchasing an additional 7,061,550 shares in the last quarter. Northern Trust Corp grew its stake in Zoetis by 1.0% in the second quarter. Northern Trust Corp now owns 5,963,894 shares of the company’s stock worth $676,842,000 after purchasing an additional 58,435 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in Zoetis by 9.5% in the second quarter. Bank of New York Mellon Corp now owns 4,420,261 shares of the company’s stock worth $501,654,000 after purchasing an additional 383,799 shares in the last quarter. Hedge funds and other institutional investors own 90.05% of the company’s stock.

Several research analysts recently issued reports on the company. Credit Suisse Group set a $138.00 price objective on Zoetis and gave the stock a “buy” rating in a research note on Friday, October 11th. Morgan Stanley increased their target price on Zoetis from $100.00 to $136.00 and gave the company an “equal weight” rating in a research report on Monday, September 30th. Barclays increased their target price on Zoetis from $120.00 to $135.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. SunTrust Banks increased their target price on Zoetis from $120.00 to $130.00 and gave the company a “hold” rating in a research report on Tuesday, August 13th. Finally, Argus set a $140.00 target price on Zoetis and gave the company a “buy” rating in a research report on Wednesday, September 4th. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $123.69.

Shares of Zoetis stock traded down $0.04 during trading on Tuesday, reaching $126.41. The company’s stock had a trading volume of 4,878 shares, compared to its average volume of 1,732,949. The company has a quick ratio of 2.87, a current ratio of 4.17 and a debt-to-equity ratio of 2.74. The company has a market cap of $61.18 billion, a price-to-earnings ratio of 40.39, a P/E/G ratio of 3.18 and a beta of 0.87. Zoetis Inc has a 1-year low of $78.90 and a 1-year high of $130.20. The company has a 50-day simple moving average of $125.74 and a two-hundred day simple moving average of $114.41.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.90 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.51 billion. Zoetis had a return on equity of 72.86% and a net margin of 22.74%. The business’s quarterly revenue was up 9.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.77 EPS. As a group, analysts anticipate that Zoetis Inc will post 3.57 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Tuesday, October 22nd will be paid a $0.164 dividend. The ex-dividend date is Monday, October 21st. This represents a $0.66 dividend on an annualized basis and a yield of 0.52%. Zoetis’s dividend payout ratio (DPR) is 21.09%.

In related news, EVP Clinton A. Jr. Lewis sold 6,123 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was sold at an average price of $120.05, for a total value of $735,066.15. Following the completion of the transaction, the executive vice president now owns 41,698 shares in the company, valued at approximately $5,005,844.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Roxanne Lagano sold 4,463 shares of the firm’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $125.99, for a total value of $562,293.37. Following the completion of the transaction, the executive vice president now owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The disclosure for this sale can be found here. Insiders sold a total of 34,332 shares of company stock valued at $4,258,182 in the last 90 days. 0.29% of the stock is currently owned by company insiders.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: How to Invest in Stocks with Increasing Dividends

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.